Syncom Formulations (India) Ltd.
NSE: SYNCOMF | BSE: 524470
₹21.41
₹-0.54
(-2.46%)
As on 19-Oct-2026IST
Market cap
₹2,013 Cr
Revenue (TTM)
₹498 Cr
P/E Ratio
23.5
P/B Ratio
4.6
Div. Yield
0.5 %
Quality Score
7/10
Growth Score
4/10
Valuation Score
5/10
Momentum Score
9/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹86 Cr
-
ROE
20.2 %
-
ROCE
26.8 %
-
Industry P/E
31.81
-
EV/EBITDA
16.6
-
Debt to Equity
0
-
Book Value
₹4.7
-
EPS
₹0.9
-
Face value
1
-
Shares outstanding
940,000,000
10 Years Aggregate
CFO
₹108.94 Cr
EBITDA
₹296.08 Cr
Net Profit
₹264.74 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Syncom Form
| 50.1 | 6.8 | 58.9 | 30.8 | 34.2 | -- | -- |
|
BSE Healthcare
| 10.0 | -7.1 | -4.1 | 6.4 | 19.0 | 12.7 | 11.4 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Syncom Form
| -31.5 | 27.0 | 70.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Syncom Form
|
21.4 | 2,013.5 | 497.8 | 85.5 | 16.3 | 21.6 | 23.5 | 4.6 |
| 6,039.5 | 15,108.3 | 2,432.1 | 169.6 | 8.7 | 20.8 | 89.1 | 16.7 | |
| 2,258.8 | 17,194.2 | 2,287.3 | 678.1 | 31.4 | 19.7 | 25.8 | 4.7 | |
| 2,010.0 | 12,302.7 | 1,479.1 | 198.6 | 18.6 | 30.3 | 61.8 | 15.2 | |
| 1,120.4 | 15,617.8 | 3,229.7 | 666.9 | 26.6 | 18.8 | 24.3 | 3.9 | |
| 3,808.7 | 17,417.1 | 2,569.8 | 735.2 | 34.4 | 19.2 | 23.7 | 4.0 | |
| 5,135.5 | 8,503.5 | 1,432.9 | 356.9 | 30.8 | 58.2 | 23.8 | 13.8 | |
| 876.2 | 17,132.0 | 1,682.5 | 273.5 | 21.0 | 11.1 | 57.6 | 6.4 | |
| 1,029.3 | 9,491.5 | 5,004.4 | 635.3 | 14.5 | 19.8 | 15.5 | 2.9 | |
| 873.3 | 7,039.8 | 872.6 | 198.4 | 29.7 | 17.4 | 35.5 | 5.8 |
Shareholding Pattern
View DetailsNews & Analysis
All News
2 min read•By Research Desk
About Syncom Form
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and... Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, creams, liquids orals, and effervescent. Further, it provides liquid vials and ampoule injections, dry vial injections and inhalers; manufacturing and trading of nutraceuticals, dietary supplements, health supplements, functional foods, herbal and ayurvedic preparations, vitamins, minerals, proteins, antioxidants, natural extracts, organic and wellness products, and all related healthcare and nutrition-based goods and real estate business. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India. Read more
-
Incorporated
1988
-
Chairman
Ankit Kedarmal Bankda
-
Managing Director
Rahul Vijay Bankda
-
Headquarters
Mumbai, Maharashtra
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Syncom Form
What is the current share price of Syncom Formulations (India) Ltd Today?
The share price of Syncom Formulations (India) Ltd is ₹21.41 (NSE) and ₹21.42 (BSE) as of 19-Oct-2026 IST. Syncom Formulations (India) Ltd has given a return of 34.24% in the last 3 years.
What is the current PB & PE ratio of Syncom Formulations (India) Ltd?
The P/E ratio of Syncom Formulations (India) Ltd is 23.54 times as on 19-Oct-2026, a 26 discount to its peers’ median range of 31.81 times.
The P/B ratio of Syncom Formulations (India) Ltd is 4.58 times as on 19-Oct-2026, a 2 discount to its peers’ median range of 4.68 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2026 |
12.67 |
2.33 |
2025 |
31.28 |
4.52 |
2024 |
41.52 |
3.65 |
2023 |
27.63 |
2.17 |
2022 |
46.32 |
4.22 |
What is the 52 Week High and Low of Syncom Formulations (India) Ltd?
The 52-week high and low of Syncom Formulations (India) Ltd are Rs 27.49 and Rs 10.21 as of 19-Oct-2026.
What is the market cap of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd has a market capitalisation of ₹ 2,013 Cr as on 19-Oct-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Syncom Formulations (India) Ltd?
Before investing in Syncom Formulations (India) Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.